CymaBay Therapeutics Inc (CBAY) Expected to Announce Earnings of -$0.36 Per Share

Equities analysts forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will report earnings per share (EPS) of ($0.36) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.41). CymaBay Therapeutics posted earnings of ($0.30) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 20%. The firm is scheduled to announce its next earnings report on Thursday, August 8th.

According to Zacks, analysts expect that CymaBay Therapeutics will report full-year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.75) to ($1.36). For the next year, analysts anticipate that the firm will post earnings of ($1.58) per share, with EPS estimates ranging from ($2.05) to ($0.91). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03).



CBAY has been the subject of a number of recent research reports. Roth Capital reiterated a “buy” rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 19th. BidaskClub downgraded CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. ValuEngine upgraded CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Leerink Swann initiated coverage on CymaBay Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $22.00 price objective for the company. Finally, Cantor Fitzgerald set a $20.00 price objective on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Sunday, April 14th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $19.56.

Several large investors have recently made changes to their positions in CBAY. Fosun International Ltd lifted its holdings in CymaBay Therapeutics by 70.8% in the 4th quarter. Fosun International Ltd now owns 792,096 shares of the biopharmaceutical company’s stock worth $6,199,000 after purchasing an additional 328,289 shares in the last quarter. MetLife Investment Advisors LLC lifted its holdings in CymaBay Therapeutics by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 43,720 shares of the biopharmaceutical company’s stock worth $484,000 after purchasing an additional 15,542 shares in the last quarter. Raymond James & Associates lifted its holdings in CymaBay Therapeutics by 7.7% in the 4th quarter. Raymond James & Associates now owns 82,205 shares of the biopharmaceutical company’s stock worth $647,000 after purchasing an additional 5,899 shares in the last quarter. Bailard Inc. purchased a new position in CymaBay Therapeutics in the 4th quarter worth approximately $984,000. Finally, LPL Financial LLC purchased a new position in CymaBay Therapeutics in the 3rd quarter worth approximately $282,000. Institutional investors own 88.57% of the company’s stock.

Shares of NASDAQ:CBAY opened at $12.30 on Friday. The company has a market cap of $866.23 million, a P/E ratio of -9.76 and a beta of 1.77. The company has a quick ratio of 18.66, a current ratio of 18.66 and a debt-to-equity ratio of 0.01. CymaBay Therapeutics has a 12-month low of $6.31 and a 12-month high of $15.00.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

See Also: Return On Assets

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.